Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Positive save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 15:30) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -2.24%
H: 7.12%
C: 4.11%
bnt211 candidate congress tumors positive update cell car-t therapy
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
Published: 2023-06-16 (Crawled : 11:00) - globenewswire.com
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: 1.77%
H: 1.74%
C: 0.35%
t-cell positive therapeutics results
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
Published: 2023-06-05 (Crawled : 20:00) - prnewswire.com
PGEN | $1.42 1.43% 1.41% 560K
|
Health Technology
|
| O: -0.75%
H: 2.26%
C: -2.26%
prgn-3005 day positive cancer
AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
aic100 positive thyroid meeting therapeutics results study
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
SNGX | $0.385 -3.75% -3.9% 490K
|
Health Technology
|
| O: 150.7%
H: 17.98%
C: -35.96%
t-cell positive treatment results study
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
yescarta europe chmp t-cell positive therapy
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
Published: 2022-07-22 (Crawled : 15:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.43%
H: 0.86%
C: -0.77%
tecartus chmp t-cell leukemia positive therapy
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
Published: 2022-06-11 (Crawled : 16:20) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
| Email alert
Add to watchlist
ctx130 crispr trial therapeutics positive results phase 1
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
CRBU | $3.86 -3.02% -3.11% 1.1M
|
Health Technology
|
| O: -22.27%
H: 0.0%
C: 0.0%
cb-010 car-t trial positive therapy phase 1
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2022-04-08 (Crawled : 18:00) - globenewswire.com
CRBU | $3.86 -3.02% -3.11% 1.1M
|
Health Technology
|
| O: 0.0%
H: 2.76%
C: -0.72%
cb-011 research preclinical car-t positive therapy cancer pre-clinical
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells
Published: 2022-03-08 (Crawled : 17:00) - biospace.com/
TCBP | $1.485 -6.01% -6.4% 110K
|
|
| O: 8.36%
H: 12.75%
C: -5.38%
myeloid leukemia pos phase 1b leukemia cel phase 1 positive t-cell acute myeloid leukemia phase 2b
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Published: 2022-01-28 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.28%
H: 1.95%
C: 1.93%
cel positive therapy chmp t-cell
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
GRTS | $0.8199 11.01% 9.92% 1.9M
|
Health Technology
|
| O: -1.56%
H: 0.83%
C: -41.5%
covid-19 covid cel phase 1 positive results vaccine t-cell
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft596 therapeutics phase 1 positive t-cell
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.04 -9.79% -10.86% 2.1M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft516 fda granted therapeutics phase 1 positive therapy t-cell designation
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
ACHL | $0.7764 -0.6% -0.61% 120K
|
Manufacturing
|
| O: 5.43%
H: 6.09%
C: -5.15%
therapeutics positive t-cell
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.